KorPath Listed by everest Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

Ransomware groups continue to target specialized research and life-sciences firms, treating proprietary scientific material and internal operational records as leverage in double-extortion schemes. In this landscape, listings on criminal leak sites often surface before any formal confirmation from the affected organization, leaving employees, partners and research collaborators uncertain about exposure.

On 12 November 2025, the biotechnology company KorPath was publicly listed by the everest ransomware group. The listing asserts that internal files were exfiltrated during a ransomware attack. The number of people affected remains unknown, and independent verification of the claim has not been published. The incident matters because KorPath works with early-stage compounds and preclinical data that could affect medical research pipelines and partner confidentiality.

What happened

Public reporting states that KorPath was listed by the everest ransomware group on 12 November 2025. According to the available summary, the group claims to have exfiltrated internal files in the course of a ransomware attack. No further technical details—such as the initial access vector, the precise date of intrusion, the volume of data taken, or any ransom demand—have been disclosed. The number of individuals potentially affected is recorded as unknown. At present the listing itself constitutes an unverified claim by the threat actor rather than a claimed breach report from KorPath or independent investigators.

Who is everest?

Everest is a ransomware operation that has been active in the double-extortion model for several years. Groups of this type typically encrypt systems, exfiltrate data, and then threaten to publish the stolen material on a dedicated leak site if payment is not received. Public reporting on everest has documented its use of common initial-access techniques, affiliate-based operations, and the publication of victim names and sample files to pressure organizations. In the present case, the group’s leak-site listing of KorPath should be treated strictly as a claim; no independent confirmation of the intrusion or of the data’s authenticity has been supplied in the available facts.

About KorPath

KorPath is a biotechnology company focused on early-stage technologies. Its work centers on identifying unique compounds and molecules intended for medical interventions, with research activity directed at pathological conditions that include cancer and neurodegenerative disorders. The firm also provides preclinical services such as ex vivo efficacy studies. Organizations of this type routinely handle proprietary research data, experimental protocols, partner agreements and internal operational records. A breach affecting such material can disrupt research timelines, compromise competitive intellectual property and raise confidentiality concerns for collaborators and study partners.

What data was at risk

The facts state that internal files were exfiltrated in a ransomware attack. No more granular inventory—such as specific file categories, employee records, patient-related data or financial documents—has been disclosed. Biotechnology firms of KorPath’s profile typically maintain research datasets, compound libraries, study protocols, contractual documents and administrative files. Because the exact contents remain unconfirmed, it is not possible to state with certainty which of these categories, if any, were among the material claimed by everest.

The real-world impact

For individuals whose information may have been present in internal files, the practical risks include potential misuse of contact details, credentials or other personal identifiers if those elements were stored alongside research material. For KorPath itself, the consequences can include temporary operational disruption, the need to notify partners and regulators where required, and the longer-term challenge of restoring confidence in the security of proprietary research. Because the scale of the incident and the precise data types remain unknown, the full extent of these effects cannot yet be quantified. Affected parties should treat any unsolicited communications that reference the company or its research with caution until more definitive information becomes available.

Were you affected?

If you have worked with, partnered with or supplied services to KorPath, consider the following practical steps:

• Monitor official statements from the company for any confirmation or guidance.
• Review recent account activity and enable multi-factor authentication on work and personal accounts that may have been used in connection with the firm.
• Be alert to phishing or social-engineering attempts that reference KorPath research or internal projects.
• Preserve any unusual communications for later reference if further investigation is needed.

Readers can also run a free exposure scan of their email address to check whether their information has already appeared in known breach datasets. Public detail on this incident remains limited; updates will depend on further disclosures by KorPath or independent verification of the everest claim.

AICompiled with AI assistance from public sources and published under our editorial standards.